{"entity":{"id":"synaffix","kind":"company","name":"Synaffix (Lonza)","aka":[],"tldr":"Licensor of the GlycoConnect site-specific ADC conjugation platform, now part of Lonza and used by dozens of ADC developers.","summary":"Synaffix, based in Oss in the Netherlands and now part of Lonza, licenses the GlycoConnect site-specific antibody-drug conjugate conjugation platform, used by dozens of ADC developers. GlycoConnect attaches payloads at the conserved Asn297 glycan to give a defined drug-to-antibody ratio, HydraSpace and toxSYN complete the platform, Lonza acquired the company in 2023 and integrated it into an end-to-end ADC service, and 2026 brought multi-target licences with Sidewinder for bispecific ADCs and with Engitix. OnCo links it to site-specific conjugation and linker chemistry, ADCs and bispecific ADCs, to ADC bioconjugation manufacturing, to Lonza, and to the idea of platform designation for linker-payloads. Whether a shared conjugation platform can earn regulatory credit that carries across products is the open question. Lonza has its own page.","asOf":"2026-09-04","links":[{"label":"Lonza ADC technology platform","url":"https://www.lonza.com/advanced-synthesis/adc-technologies-platform"}],"tags":[],"related":[],"cancers":[],"sections":["adcs","drug-discovery"],"technologies":["site-specific-conjugation","adc","bispecific-adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Oss","country":"NL","companyType":"biotech","website":"https://synaffix.com","investors":[],"funding":[]},"route":"/companies/synaffix/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"technology":[{"id":"adc-cdmo-manufacturing","kind":"technology","name":"ADC bioconjugation manufacturing (CDMOs)","route":"/technologies/adc-cdmo-manufacturing/"},{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/"},{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/"}],"idea":[{"id":"idea-reg-adc-platform-designation","kind":"idea","name":"Platform designation for ADC linker-payloads so manufacturing data carry across","route":"/ideas/idea-reg-adc-platform-designation/"}],"company":[{"id":"lonza","kind":"company","name":"Lonza","route":"/companies/lonza/"}]}}